Drug-impaired driving crashes present a more complex liability analysis than alcohol-impaired cases because the legal standards, the toxicology, and the jury education challenge are all more demanding. There is no breathalyzer for cannabis, no universal blood concentration standard for most impairing substances, and no uniform per se impairment threshold recognized across all jurisdictions. Yet drug-impaired drivers cause crashes at rates that have increased substantially as cannabis legalization has spread and as prescription opioid use remains prevalent among the driving population. Building the DUID case requires understanding what the toxicology actually shows, what expert testimony can reliably establish, and where the law of your specific jurisdiction draws the line between legal drug use and impaired operation.
Per Se vs. Impairment-Based Legal Standards
States have taken two approaches to drug-impaired driving. A small number of states (including Utah for THC, and several others for controlled substances) have enacted per se DUID laws that establish a specific blood concentration above which the driver is legally impaired, regardless of observed behavioral indicators. Most states use an impairment-based standard: the prosecution or plaintiff must show that the driver was actually impaired in their ability to operate the vehicle safely, not merely that a detectable amount of a controlled or impairing substance was present.
For plaintiff counsel, the distinction matters because the per se standard, where it applies, allows the toxicology test result alone to establish the liability element of impairment. The impairment-based standard requires the toxicology result plus corroborating evidence of actual driving impairment: erratic lane changes, slowed reaction time, failure to brake before impact, witness observations of the driver's demeanor and behavior, and officer observations at the scene.
Cannabis Impairment: The Toxicology Problem
THC (tetrahydrocannabinol), the psychoactive compound in cannabis, is metabolized differently than alcohol. Blood THC concentration peaks during intoxication and then declines within hours in casual users. However, THC metabolites (primarily THC-COOH) persist in blood and urine for days to weeks depending on frequency of use. Chronic users may show elevated THC-COOH levels even when they are not acutely impaired, and may show lower peak blood THC levels at the time of intoxication than casual users because of tolerance and metabolic difference.
The practical implication for plaintiff cases: a positive blood THC test drawn hours after the crash may show the presence of THC metabolites that reflect use from days before the crash, not impairment at the time of the incident. Conversely, a driver who consumed cannabis within two hours of the crash may show a blood THC level that reflects recent use, particularly if the test was drawn promptly. The timing of the blood draw relative to the crash, and the specific compounds tested (THC vs. metabolites), determine what the toxicology actually proves. Retain a toxicologist expert who can explain the detection window, the pharmacokinetics of THC elimination, and what the specific test result in your case is consistent with regarding timing of use.
Prescription Drug Impairment
Prescription opioids (hydrocodone, oxycodone, oxymorphone), benzodiazepines (alprazolam, clonazepam, diazepam), sleep aids (zolpidem), and antihistamines (diphenhydramine) are all documented causes of driving impairment when taken in therapeutic doses. Unlike illicit drug use, prescription drug impairment creates an additional negligence vector: the prescribing physician's duty to warn the patient about driving while taking the medication, and the employer's obligation if the driver was using a prescribed medication in an occupational driving context.
In prescription drug impairment cases, obtain the medical records of the at-fault driver, including all prescriptions filled in the 90 days before the crash, the prescribing physician's instructions, and any warnings given to the patient about driving while taking the medication. The drug warning insert for most opioids and benzodiazepines explicitly states that driving or operating heavy machinery should be avoided while taking the medication. A driver who ignored that warning after receiving it from the prescribing physician or pharmacist has a more difficult comparative fault defense than a driver who claims no impairment was caused by the medication.
Drug Recognition Expert Protocol
When police respond to a crash involving a suspected drug-impaired driver, the Drug Recognition Expert (DRE) protocol is sometimes administered. A DRE-certified officer conducts a structured 12-step evaluation of the driver's physiological condition, including vital signs, pupil size, muscle tone, and behavioral indicators. The DRE protocol is designed to identify the drug category responsible for observed impairment (depressants, stimulants, cannabis, dissociatives, etc.) and is admissible in most jurisdictions as expert opinion evidence of impairment.
If a DRE evaluation was conducted, obtain the complete evaluation report and results. If the DRE evaluation supported an impairment finding that the defense seeks to exclude, the opposing expert challenge to DRE reliability is an available defense argument in some jurisdictions. Know your jurisdiction's case law on DRE admissibility before building the case around the DRE report.
Insurance Coverage and Punitive Damages
Most personal automobile insurance policies do not exclude coverage for drug-impaired driving the way some exclude criminal acts. The coverage analysis for a drug-impaired defendant is generally the same as for an alcohol-impaired defendant: the liability policy applies, and the plaintiff may pursue underinsured motorist coverage if the at-fault driver's limits are inadequate. Punitive damages are available in drug-impaired driving cases in states that permit punitive recovery for conscious disregard of known risks, and knowing drug impairment while choosing to drive satisfies that standard in most jurisdictions.
For the wrongful death damages framework in drug-impaired driving fatalities, including the punitive damages analysis in applicable states, see wrongful death practice coverage. For verdict benchmarks and settlement ranges in DUID cases with specific drug categories, see case law and settlements data. For UM/UIM coverage strategy when the drug-impaired driver's policy is insufficient, see the full coverage framework in auto accidents practice.